Karl Wallendszus

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.

Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.

Journal: Health technology assessment (Winchester, England)

Published: May 12, 2026

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics.

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics.

Journal: American heart journal

Published: January 25, 2026

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: October 29, 2024

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Journal: The New England journal of medicine

Published: October 25, 2024

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Journal: NEJM evidence

Published: June 21, 2024

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Journal: Trials

Published: March 11, 2024

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.

Journal: Contemporary clinical trials communications

Published: March 29, 2023

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Journal: Heart (British Cardiac Society)

Published: March 03, 2023

Empagliflozin in Patients with Chronic Kidney Disease.

Empagliflozin in Patients with Chronic Kidney Disease.

Journal: The New England journal of medicine

Published: November 04, 2022

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.

Journal: JAMA network open

Published: December 28, 2021

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.

Journal: European heart journal

Published: October 17, 2021

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

Journal: European heart journal

Published: May 25, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026